Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
Lists
Only you see this
Abstract
These analyses support the approved SG dosing regimen of 10 mg/kg as intravenous infusion on days 1 and 8 of 21-day cycles and did not identify a need for dose adjustment based on evaluated covariates or disease characteristics.
BibTeX
@inproceedings{sathe2024population,
author = {Abhishek G. Sathe and Indrajeet Singh and Pratap Singh and Paul M. Diderichsen and Xiaohui Wang and Peter Chang and Atiya Taqui and See Phan and Sandhya Girish and Ahmed A. Othman},
title = {{Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors}},
booktitle = {Clinical},
year = {2024},
doi = {10.1007/s40262-024-01366-3},
}Loading related content...